DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES

• US 20150212092A1
• Filed: 11/06/2014
• Published: 07/30/2015
• Est. Priority Date: 11/15/2002
• Status: Abandoned Application

• Current Assignee: Jyant Technologies, Inc.
• Original Assignee: Jyant Technologies, Inc.
• Inventors: LILLARD, James W. Jr., Singh, Rajesh, Singh, Shailesh
• Application Number:
  US14/534,982
• Publication Number:
  US 20150212092A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/521 Chemokines
• CPC Class Codes: G01N 2333/522 Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
• CPC Class Codes: G01N 2333/7158 for chemokines
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57426 leukemia
• CPC Class Codes: G01N 33/5743 of skin, e.g. melanoma
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells
• CPC Class Codes: G01N 33/57496 involving intracellular compounds

Abstract

Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.

Claims

1. A method for detecting the presence of cancer in a subject, comprising:

detecting the level of expression of one or more cancer marker in a biological sample obtained from said subject; and

comparing the level of expression of said one or more cancer markers in said biological sample to a normal level of expression of said one or more cancer markers,

wherein a higher than normal level of expression of said one or more cancer markers in said biological sample is indicative of the presence of cancer in said subject,

wherein said normal level of expression of said one or more cancer markers is a predetermined value or is obtained from a control sample of known normal non-cancerous cells of the same origin or type as said biological sample, and

wherein said cancer is carcinoma, and

wherein said one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5.

2. The method of claim 1, wherein said one or more cancer markers further comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6.

3. The method of claim 2, wherein said one or more cancer markers further comprises one or more cancer markers selected from the group consisting of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14, CXCL15, CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL24, CCL25, CCL25-1, CCL25-2, CCL27, CCL28, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, XCL1, XCL2, XCR1, CX3CR1, CX3CL1, RNA binding motif 3 (“

RBM3”

), carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromgranin A (CGA), dehydroepiandrosterone (DHEA), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prolactin, B7-H3, seprase polypeptide, anti-p53, osteopontin, ferritin, lysophosphatidyl choline, kinesin family member 4A (KIF4A), Neural pentraxin I (NPTX1) and fibroblast growth factor receptor 1 oncogene partner (FGFR1OP) protein.

5. The method of claim 1, wherein said one or more cancer markers further comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6.

6. The method of claim 5, wherein said one or more cancer markers further comprises one or more cancer markers selected from the group consisting of CCL25, CCL27, CXCL1, CXCL2, CXCL3, CXCL7, CXCL8, CXCL12, CX3CL1, CCR9, CCR10, CXCR1, CXCR2, CXCR4, and CX3CR1.

17. The method of claim 1, wherein said biological sample is a plasma sample, a saliva sample, or an urine sample.

4. (canceled)

7-16. -16. (canceled)

18. A method for assessing the prognosis of a subject with a cancer, comprising:

determining the expression level of one or more cancer markers in a biological sample from said subject, and

comparing the level of expression of said one or more cancer markers in said biological sample to a control level of expression of said one or more cancer markers,

wherein a higher level of expression of said one or more cancer markers in the biological sample relative to said control level indicates that the prognosis of said subject is poor,

wherein a lower or similar level of expression of said one or more cancer markers in said biological sample relative to said control level indicates that the prognosis of said subject is good,

wherein a poor prognosis indicates that said cancer is of an aggressive or invasive type, wherein said cancer is carcinoma, and

wherein said one or more cancer markers comprise CXCL13 or CXCR5 or both CXCL13 and CXCR5.

19. The method of claim 18, wherein said one or more cancer markers further comprise CXCL16 or CXCR6 or both CXCL16 and CXCR6.

20. A method for monitoring the course of cancer treatment in a subject, comprising:

determining the expression levels of one or more cancer markers in one or more biological samples obtained from said subject during or after said treatment, and

comparing the level of expression of said one or more cancer markers in said one or more biological samples to a control level of expression of said one or more cancer markers,

wherein said control level of said one or more cancer markers is a pre-treatment level of said one or more cancer markers in said subject or a predetermined reference level,

wherein said treatment is deemed efficacious if said one or more cancer markers in said one or more biological samples is similar to or lower than said control level,

wherein said cancer is carcinoma, and

wherein said one or more cancer markers comprise CXCL13 or CXCR5 or both CXCL13 and CXCR5.

21. The method of claim 20, wherein said one or more cancer markers further comprise CXCL16 or CXCR6 or both CXCL16 and CXCR6.

22. A kit for detecting cancer or monitoring cancer progression, comprising:

reagents for determining expression of CXCL13 and/or CXCR5 in a biological sample; and

instructions for how to use said reagents,

wherein said reagents comprise an anti-CXCL13 antibody, an anti-CXCR5 antibody, or both and wherein said cancer is carcinoma.

23. The kit of claim 22, further comprising:

reagents for determining expression of CXCL16 and/or CXCR6 in a biological sample; and

instructions for how to use said reagents,

wherein said reagents comprise an anti-CXCL16 antibody, an anti-CXCR6 antibody, or both.